CYBN - Cybin Submits IND Application to FDA for CYB003 Phase 1/2a Clinical Trial

Image

Cybin Inc. (NEO: CYBN) (NYSE:CYBN), a biopharmaceutical company focused on advancing “psychedelics into therapeutics”, just announced a monumental milestone toward advancing CYB003 into clinical development. CYB003 is a deuterated psilocybin analog designed to achieve less variability, faster onset of action, shorter duration of effect and potentially better tolerability than pure psilocybin. CYB003 has the potential to effectvely treat major depressive disorder (MDD) and alcohol use disorder (AUD).

On May 26, Cybin (NEO: CYBN) (NYSE:CYBN) announced that it had submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) ...